Autopsy report · NCT06235242
GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer
Cause of deathFunding or business
“The study was terminated from a business perspective.”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 2 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Grit Biotechnology
- Sponsor type
- Industry
- Conditions
- Adult; Non-small Cell Lung Cancer
- Interventions
- GT201 injection in combination with teraplizumab injection
- Participants
- 2
- Sites
- 3
- Countries
- China
Trials that died the same way
- Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
“The study was terminated due to a business decision.” - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
“The study was terminated due to strategic business reasons.” - A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
“Study terminated for strategic business reasons” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses
“Study was terminated due to a business decision to cancel the entire project.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.